Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Gynecologic Oncology
|
August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
Susana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial
Marion Procter, Thomas M Suter, Evandro de Azambuja, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
The Lancet. Oncology
|
December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
Robert D Morgan, Iain A McNeish, Adrian D Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology
|
February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Jean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Lancet (London, England)
|
December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
The Lancet. Oncology
|
June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Andrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Nature Genetics
|
August 15, 2018
Copy number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre, Teodora E Goranova, Dilrini De Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)
Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Gynecologic Oncology
|
August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
Susana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2010
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial
Marion Procter, Thomas M Suter, Evandro de Azambuja, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
The Lancet. Oncology
|
December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
Robert D Morgan, Iain A McNeish, Adrian D Cook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology
|
February 22, 2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Jean-Emmanuel Kurtz, Val Gebski, Vladyslav Sukhin, et al.
Lancet (London, England)
|
December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
The Lancet. Oncology
|
June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Andrew R Clamp, Elizabeth C James, Iain A McNeish, et al.
Nature Genetics
|
August 15, 2018
Copy number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre, Teodora E Goranova, Dilrini De Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)
Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Page
of 8